HistoSonics, Inc. was created to advance the development of histotripsy, a revolutionary science discovered and developed by leading scientists at the University of Michigan, USA to provide im-proved therapies for patients. Their exclusive license to intellectual property, significant financial support and strategic partnerships have helped HistoSonics develop Robotically Assisted Sonic Therapy (RAST), a new platform being developed for cancer care that uses histotripsy. HistoSonics’ team of experienced specialists and industry leaders is based in Ann Arbor, Michigan. EUROICC and HistoSonics joined efforts in R&D of:

- Signal generator for Vortx Rx - a therapy device which represents a stride in the treatment of cancer.
- Histotripsy – noninvasive surgical knife capable of generating ultrasonic pulse sequences powerful enough to break down tissue whistle leaving the surrounding areas unharmed.